Ceritinib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Ceritinib is used to treat metastatic (cancer that has already spread) non-small cell lung cancer in patients who have a certain type of abnormal anaplastic lymphoma kinase (ALK) gene. Your doctor will test for the presence of this gene. Ceritinib is an antineoplastic (cancer) agent.Ceritinib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Ceritinib Nitroso Impurity 2 CAS NO:NA chemically represented as N-(5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)-N-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)nitrous amide. Synchemia is the leading manufacturing and exporter of Ceritinib Nitroso Impurity 2 . We supply Ceritinib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143204 |
| CAS No | NA |
| Mol.F. | C30H31N9O9S |
| Mol.Wt. | 693.7 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143205 |
| CAS No | NA |
| Mol.F. | C30H31N9O9S |
| Mol.Wt. | 693.7 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143206 |
| CAS No | NA |
| Mol.F. | C45H49ClN8O9S |
| Mol.Wt. | 913.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143207 |
| CAS No | NA |
| Mol.F. | C45H49ClN8O9S |
| Mol.Wt. | 913.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143208 |
| CAS No | NA |
| Mol.F. | C45H51ClN8O6S |
| Mol.Wt. | 867.5 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143209 |
| CAS No | NA |
| Mol.F. | C45H49ClN8O9S |
| Mol.Wt. | 913.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143210 |
| CAS No | NA |
| Mol.F. | C47H51ClN8O9S |
| Mol.Wt. | 939.5 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143211 |
| CAS No | NA |
| Mol.F. | C45H49ClN8O9S |
| Mol.Wt. | 913.44 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143212 |
| CAS No | NA |
| Mol.F. | C20H31N7OS2 |
| Mol.Wt. | 449.64 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143213 |
| CAS No | NA |
| Mol.F. | C21H33N7OS2 |
| Mol.Wt. | 463.66 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143214 |
| CAS No | NA |
| Mol.F. | C21H33N7OS2 |
| Mol.Wt. | 463.66g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143215 |
| CAS No | NA |
| Mol.F. | C11H16N4OS |
| Mol.Wt. | 252.34 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143216 |
| CAS No | NA |
| Mol.F. | C11H18N4O2S |
| Mol.Wt. | 270.35g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143217 |
| CAS No | NA |
| Mol.F. | C10H18N4O3S |
| Mol.Wt. | 274.34 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143218 |
| CAS No | NA |
| Mol.F. | C15H24N4O5S |
| Mol.Wt. | 372.44 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143219 |
| CAS No | NA |
| Mol.F. | C10H16N4O2S |
| Mol.Wt. | 256.32 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |